GenrAb Completes $5.6 Million Financing to Accelerate Development of its Lead Antibody Therapy (TGM-010) and Expand Pipeline of Neuroprotective Candidates

GenrAb advances TGM-010, a neuron-targeting antibody, with new seed funding.

GenrAb Expands its Exclusive License and Sponsored Research Agreements with UTSW

GenrAb expands exclusive license with UTSW, adding over 250 anti-neuronal antibodies to its growing pipeline.

Issuance of US Patents that cover GenrAb’s lead antibody therapy (TGM-010)

GenrAb secures US patents for its lead antibody TGM-010, advancing neuroprotective therapy development.

GenrAb establishes its HQ @ BioLabs in Dallas TX

GenrAb selects BioLabs @ Pegasus Park, Dallas, as its HQ for antibody therapy development and expansion.